Analytical Data
-
Gene name
ADAMTS17
- Application
-
Alternative Names
ADAM-TS 17; ADAM-TS17; ADAMTS 17; ADAMTS-17; ADAMTS17
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TE56
-
Expression Region
543-650aa
-
AA Sequence
DGDWSPWGAWSMCSRTCGTGARFRQRKCDNPPPGPGGTHCPGASVEHAVCENLPCPKGLPSFRDQQCQAHDRLSPKKKGLLTAVVVDDKPCELYCSPLGKESPLLVAD
-
Molecular Weight
37.62 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ADAMTS17 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs 17) is a member of the ADAMTS family, known for its role in extracellular matrix (ECM) remodeling and its involvement in various pathological processes. Recent research has highlighted its significance in connective tissue disorders, particularly in skeletal development and disease. Mutations in the ADAMTS17 gene have been linked to a range of heritable connective tissue disorders, including a unique form of skeletal dysplasia characterized by unusually short stature and skeletal abnormalities. The recombinant protein of ADAMTS17 has become a focal point of research due to its potential therapeutic applications and as a tool for understanding the molecular mechanisms underlying its functions in ECM dynamics. Studies utilizing the recombinant form of ADAMTS17 aim to elucidate its enzymatic activity, substrate specificity, and interactions with other proteins within the ECM. Additionally, the investigation of ADAMTS17 in various tissue types can provide insights into its role in normal physiology and disease states, thereby advancing our understanding of connective tissue biology and offering avenues for targeted interventions in related conditions. Overall, the exploration of ADAMTS17 through recombinant protein studies holds promise for unveiling new therapeutic strategies for managing connective tissue disorders and enhancing our comprehension of ECM biology.
